Automate Your Wheel Strategy on RXRX
With Tiblio's Option Bot, you can configure your own wheel strategy including RXRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RXRX
- Rev/Share 0.1544
- Book/Share 2.2023
- PB 2.2159
- Debt/Equity 0.0958
- CurrentRatio 3.5797
- ROIC -0.5551
- MktCap 2096984717.0
- FreeCF/Share -0.9374
- PFCF -5.3601
- PE -3.1384
- Debt/Assets 0.0676
- DivYield 0
- ROE -0.7607
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | RXRX | Morgan Stanley | -- | Equal Weight | -- | $5 | July 3, 2025 |
News
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.
Read More
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT.
Read More
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
Published: February 21, 2025 by: MarketBeat
Sentiment: Neutral
Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals.
Read More
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Read More
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Read More
About Recursion Pharmaceuticals, Inc. (RXRX)
- IPO Date 2021-04-16
- Website https://www.recursion.com
- Industry Biotechnology
- CEO Christopher C. Gibson
- Employees 800